Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment crawled time : 15:01 save search
Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting
Published: 2021-02-19 (Crawled : 15:01) - globenewswire.com
PHVS | $21.7 3.98% 3.82% 89K
|
|
| O: 1.46%
H: 18.98%
C: 15.13%
treatment
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
Published: 2021-01-28 (Crawled : 15:01) - globenewswire.com
AYLA | $0.5036 5.84% -0.7% 0
|
Health Technology
|
| O: -9.93%
H: 10.29%
C: 5.55%
cancer treatment phase 2 breast cancer trial
Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
Published: 2021-01-12 (Crawled : 15:01) - globenewswire.com
CAPR | $4.81 -2.63% -2.7% 480K
|
Health Technology
|
| O: 17.31%
H: 15.73%
C: -4.66%
therapy treatment collaboration cap-1002 duchenne
Blueprint Medicines Submits Supplemental New Drug Application to FDA for AYVAKIT™ (avapritinib) for the Treatment of Advanced Systemic Mastocytosis
Published: 2020-12-17 (Crawled : 15:01) - biospace.com/
BPMC | $92.32 1.89% 1.85% 790K
|
Health Technology
|
| O: 0.01%
H: 0.78%
C: 0.66%
drug fda treatment new drug application
Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH
Published: 2020-12-07 (Crawled : 15:01) - globenewswire.com
APLS G | $48.69 2.2% 2.16% 1.2M
|
Health Technology
|
| O: 0.32%
H: 3.29%
C: 2.33%
treatment response
Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-Thalassemia
Published: 2020-12-05 (Crawled : 15:01) - globenewswire.com
EDIT | News | $5.465 -2.41% -2.47% 1.6M
|
Health Technology
| Email alert
Add to watchlist
disease treatment preclinical pre-clinical
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
Published: 2020-12-03 (Crawled : 15:01) - globenewswire.com
AKTX | $1.22 3.39% 3.28% 4.8K
|
Health Technology
|
| O: 0.61%
H: 20.12%
C: 13.41%
disease treatment potential
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.